A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3

• David B. Shultz,

  Affiliation Princess Margaret Cancer Centre, Toronto, Ontario, Canada

  ⨯
• Jonathan Pai,

  Affiliation School of Medicine, University of California San Francisco, San Francisco, United States of America

  ⨯
• Wayland Chiu,

  Affiliation Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, United States of America

  ⨯
• Kendall Ng,

  Affiliation Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, United States of America

  ⨯
• Madeline G. Hellendag,

  Affiliation Kaiser Permanente Medical Center, San Francisco, United States of America

  ⨯
• Gregory Heestand,

  Affiliation Moores Cancer Center, University of California San Diego, La Jolla, CA, United States of America

  ⨯
• Daniel T. Chang,

  Affiliation Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, United States of America

  ⨯
• Dongsheng Tu,

  Affiliation NCIC Clinical Trials Group, Queen's University, Kingston, Canada

  ⨯
• Malcolm J. Moore,

  Affiliation British Columbia Cancer Agency, Vancouver, British Columbia, CA, United States of America

  ⨯
• Wendy R. Parulekar,

  Affiliation NCIC Clinical Trials Group, Queen's University, Kingston, Canada

  ⨯
• Albert C. Koong

  * E-mail: akoong@stanford.edu

  Affiliation Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, United States of America

  ⨯